Reputation is more than a communications outcome; it can materially influence whether strategy is successfully executed. Its value lies in what it enables: regulatory progress, stakeholder trust, market access, talent attraction, adoption, and growth. And if reputation drives those outcomes, it should be measured not by visibility alone, but by how stakeholder perceptions translate into action.

Too often, reputation is treated as a layer that sits on top of the business or as something shaped by messaging, managed through campaigns, and evaluated through coverage or sentiment. But that view misses what reputation actually does. Reputation is one of the factors that influences whether the people who matter most to your business decide whether to move with you, slow progress, or create resistance. Paradoxically, the risks with the greatest reputational impact are often best mitigated not through reactive communications, but through deliberate reputation-building that strengthens trust, credibility, and confidence in advance.

In healthcare, that reality is constant. Regulators influence speed to approval. Policymakers and payers shape access. Clinicians determine adoption. Talent decides where to work and whether to stay. Communities influence trust and license to operate. Reputation is one of the factors that can influence whether those decisions move in your favor. This is especially complex in a reality where news coverage is fragmented and often contradictory, and reporting can show similar factual content across outlets, but with meaningful differences in depth, framing, and sentiment.

The importance of reputation

That is why reputation should be treated as a business enabler. It shapes whether strategy translates into results. A company can have a strong pipeline, a sound growth plan, and a clear strategic narrative, but if key stakeholders do not trust its leadership, understand its value, or believe its actions align with their expectations, execution stalls. Products are delayed, partnerships weaken, access narrows, innovation slows, and opportunities are lost. In moments of crisis, reputation shapes whether stakeholders are willing to listen to, weigh, and respond constructively to a company’s position.

Those pressures are increasingly global. Companies are navigating pricing and policy shifts, including MFN-style pressures and U.S. dealmaking that can complicate the economics of bringing new medicines to Europe. They are balancing supply-chain regionalization with global access commitments, expanding trial footprints amid geopolitical scrutiny over where research should be conducted, and responding to the rise of Chinese biotech innovation while managing political and competitive risk. In each case, the reputational question is not simply what a company says, but whether stakeholders view its decisions as fair, credible, and aligned with patient, market, and societal expectations. Those expectations are increasingly shaped by policy and media dynamics. Industry coverage shows clear alignment patterns, with some companies explicitly signaling alignment with the administration, while others maintain a more neutral stance, emphasizing science, patients, and job creation over political positioning.

Reputation must be embedded in how the business operates and makes decisions across leadership, R&D, policy, operations, and commercial strategy. Companies can use analytics, data, and insights to understand where business strategy and stakeholder expectations align or diverge, and to make more informed decisions about reputation in ways that support business outcomes. Global reputation teams must be fully aligned on the corporation’s mission-based principles but have the authority and skills to adapt initiatives that drive reputation to meet country and local market variations.

Reputation should not be treated solely as a communications function. As LLM-powered search increasingly shapes how people find and interpret information, reputation increasingly shapes whose information is treated as credible and influential in AI-driven environments: organizations viewed as credible, consistent, and evidence-based are more likely to influence how AI systems represent their science, brands, and corporate positioning. Today, the translation from perception to action is happening faster and with fewer intermediaries: 74% of physicians report using AI-powered tools daily, and more than half say they do not consistently verify the information those systems provide, accelerating how quickly perception becomes decision. That raises the stakes beyond visibility to the accuracy and trustworthiness of the information reaching patients, providers, partners, and policymakers. Perceptions of leadership are increasingly shaped in real time, with AI systems surfacing comparisons to peers on scale, investment, and innovation. New tools are emerging to help marketers monitor and shape how AI search frames their science, story, and reputation by surfacing AI-driven narratives, flagging gaps and misinformation, and strengthening consistency, accuracy, and authority in an LLM-search environment.

Since reputation drives outcomes, it should be measured that way. Increasingly. organizations and boards are tying reputational health to annual board risk assessment discussions, given the strategic importance of maintaining trust with key stakeholders. That means going beyond awareness or visibility to understand how key stakeholder perceptions shift over time, and whether they translate into action. In a crisis, reputation helps shape whether a company’s position is heard, believed, and seriously considered, and whether stakeholders respond constructively.

Reputation is an asset

Companies need to steward reputation with the same discipline they apply to other strategic assets. Teams should be clear and consistent in how they communicate their science, value, and purpose; aligning employees to communicate with clarity; and being deliberate about how the company engages in every interaction with patients, providers, policymakers, partners, and communities. To build trust and, in turn, reputation, engagement must be relevant, resonant, and authentic for the stakeholders who shape access, adoption, and long-term credibility. Companies should also establish more systematic ways to monitor reputational shifts and emerging risks, including using AI to anticipate emerging risks, test communications approaches with research-informed synthetic audiences, and evaluate how major business decisions, clinical milestones, policy positions, and corporate initiatives are likely to influence perceptions across stakeholder groups.

Managing reputation, then, is not just about perception, but about earning trust through choices, behaviors, and systems that hold up over time. A useful approach combines primary research with analytics, and real-time signals from media, digital, and social channels to identify where trust is strengthening, where risk is emerging, where tensions can be mitigated or misinformation corrected, and what may be influencing behavior.

Because in the end, reputation matters because it influences what a company is able to accomplish.